A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants with Advanced and/or Unresectable Biliary Tract Carcinoma

This Study is
No Longer Enrolling

Details
Age

Adult

Type of Study

Treatment

Locations

University of Colorado Hospital

Study ID

Protocol Number: 19-1503

More information available at ClinicalTrials.gov: NCT04003636

Categories

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers